drugset / Trial / NCT00661141

Phase IIa Study of Fomepizole for Acetaldehyde Toxicity After Ethanol Exposure in Subjects With Altered Ethanol Metabolism

NCT00661141

Phase 2 Completed 32 enrolled Amgen
RandomizedParallel-groupTriple-blindTreatment

Summary

This trial will evaluate if fomepizole (4-methylpyrazole) can treat symptoms associated with alcohol intolerance due to aldehyde dehydrogenase 2 (ALDH2) deficiency, an inherited metabolic disorder. These symptoms include flushing, nausea, headache, shortness of breath and dizziness, resulting from exposure to acetaldehyde, the primary metabolite of ethanol. Long-term, serious health risks have been associated with repeated exposure to acetaldehyde, a carcinogen, among ALDH2-deficient individuals.

Timeline

Start
2008-04
Primary completion
2008-06
Completion
2008-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Fomepizole Small molecule 1 mg/kg Oral
Subject Fomepizole Small molecule 3 mg/kg Oral
Subject Fomepizole Small molecule 5 mg/kg Oral
Subject Fomepizole Small molecule 7 mg/kg Oral

Indications

No indication recorded.